Mortality among adults living with HIV treated for tuberculosis based on positive, negative, or no bacteriologic test results for tuberculosis: the IeDEA consortium

Background In resource-constrained settings, people living with HIV (PLWH) treated for tuberculosis (TB) despite negative bacteriologic tests have a higher mortality than those treated with positive tests. Many PLWH are treated without bacteriologic testing; their mortality compared to those with bacteriologic testing is uncertain. Methods We conducted an observational cohort study among PLWH ≥ 15 years of age who initiated TB treatment at clinical sites affiliated with four regions of the International epidemiology Databases to Evaluate AIDS (IeDEA) consortium from 2012-2014: Caribbean, Central and South America, and Central, East, and West Africa. The primary exposure of interest was the TB bacteriologic test status at TB treatment initiation: positive, negative, or no test result. The hazard for death in the 12 months following TB treatment initiation was estimated using the Cox proportional hazard model, adjusted for patient- and site-level factors. Missing covariates were multiply imputed. Results Among 2,091 PLWH included, the median age at TB treatment initiation was 36 years, 44% were female, 53% had CD4 counts ≤ 200 cells/mm3, and 52% were on antiretroviral treatment (ART). Compared to patients with positive bacteriologic tests, the adjusted hazard for death was higher among patients with no test results (HR 1.56, 95% CI 1.08-2.26) but not different than those with negative tests (HR 1.28, 95% CI 0.91-1.81). Older age was also associated with a higher hazard for death, while being on ART, having a higher CD4 count, West Africa region, and tertiary facility level were associated with lower hazards for death. Conclusion PLWH treated for TB with no bacteriologic test results were more likely to die than those treated with positive tests, underscoring the importance of TB bacteriologic diagnosis in resource-constrained settings. Research is needed to understand the causes of death among PLWH treated for TB in the absence of positive bacteriologic tests.

[1]  T. Sterling,et al.  HIV-related tuberculosis: mortality risk in persons without vs. with culture-confirmed disease. , 2019, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[2]  M. Egger,et al.  Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries , 2018, bioRxiv.

[3]  X. Bi,et al.  Risk factors for extrapulmonary dissemination of tuberculosis and associated mortality during treatment for extrapulmonary tuberculosis , 2018, Emerging Microbes & Infections.

[4]  K. Naidoo,et al.  Mortality and treatment response amongst HIV-infected patients 50 years and older accessing antiretroviral services in South Africa , 2018, BMC Infectious Diseases.

[5]  Timothy M Wolock,et al.  The global burden of tuberculosis: results from the Global Burden of Disease Study 2015 , 2017, The Lancet. Infectious diseases.

[6]  M. Borgdorff,et al.  Reduction of HIV-associated excess mortality by antiretroviral treatment among tuberculosis patients in Kenya , 2017, PloS one.

[7]  P. Onyebujoh,et al.  Stronger tuberculosis laboratory networks and services in Africa essential to ending tuberculosis , 2017, African journal of laboratory medicine.

[8]  M. Yotebieng,et al.  Low implementation of Xpert MTB/RIF among HIV/TB co-infected adults in the International epidemiologic Databases to Evaluate AIDS (IeDEA) program , 2017, PloS one.

[9]  G. Medhin,et al.  Factors Associated with Mortality of TB/HIV Co-infected Patients in Ethiopia , 2017, Ethiopian journal of health sciences.

[10]  Isabel K. M. Yan,et al.  Antiretroviral Treatment Scale-Up and Tuberculosis Mortality in High TB/HIV Burden Countries: An Econometric Analysis , 2016, PloS one.

[11]  Jeffrey N. Martin,et al.  Implementation and Operational Research: Use of Symptom Screening and Sputum Microscopy Testing for Active Tuberculosis Case Detection Among HIV-Infected Patients in Real-World Clinical Practice in Uganda , 2016, Journal of acquired immune deficiency syndromes.

[12]  S. Lawn,et al.  Xpert MTB/RIF - why the lack of morbidity and mortality impact in intervention trials? , 2016, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[13]  M. Lindegren,et al.  Implementation of Tuberculosis Intensive Case Finding, Isoniazid Preventive Therapy, and Infection Control ("Three I's") and HIV-Tuberculosis Service Integration in Lower Income Countries , 2016, PloS one.

[14]  D. Silva,et al.  Characteristics of Patients with Smear-Negative Pulmonary Tuberculosis (TB) in a Region with High TB and HIV Prevalence , 2016, PloS one.

[15]  M. Noubom,et al.  Determinants of death among tuberculosis patients in a semi urban diagnostic and treatment centre of Bafoussam, West Cameroon: a retrospective case-control study , 2015, The Pan African medical journal.

[16]  S. Lawn,et al.  Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis , 2015, AIDS.

[17]  Alimuddin Zumla,et al.  Tackling the tuberculosis epidemic in sub-Saharan Africa--unique opportunities arising from the second European Developing Countries Clinical Trials Partnership (EDCTP) programme 2015-2024. , 2015, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[18]  B. Lindtjørn,et al.  Trends of Tuberculosis Case Notification and Treatment Outcomes in the Sidama Zone, Southern Ethiopia: Ten-Year Retrospective Trend Analysis in Urban-Rural Settings , 2014, PloS one.

[19]  L. Rodrigues,et al.  Empirical treatment for TB in HIV: lessons from a cohort study of people living with HIV treated in Recife, Brazil , 2014, BMC Public Health.

[20]  P. Mason,et al.  Impact of Xpert MTB/RIF on Antiretroviral Therapy-Associated Tuberculosis and Mortality: A Pragmatic Randomized Controlled Trial , 2014, Open forum infectious diseases.

[21]  Grant Theron,et al.  Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial , 2014, The Lancet.

[22]  K. Anastos,et al.  Tuberculosis in Antiretroviral Treatment Programs in Lower Income Countries: Availability and Use of Diagnostics and Screening , 2013, PloS one.

[23]  L. Scott,et al.  Time to Treatment and Patient Outcomes among TB Suspects Screened by a Single Point-of-Care Xpert MTB/RIF at a Primary Care Clinic in Johannesburg, South Africa , 2013, PloS one.

[24]  Denis Nash,et al.  TB Diagnostic Capacity in Sub-Saharan African HIV Care Settings , 2012, Journal of acquired immune deficiency syndromes.

[25]  Kara Wools-Kaloustian,et al.  Cohort Profile: the international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. , 2012, International journal of epidemiology.

[26]  M. Lourenço,et al.  Factors Impacting Early Mortality in Tuberculosis/HIV Patients: Differences between Subjects Naïve to and Previously Started on HAART , 2012, PloS one.

[27]  F. Altice,et al.  Treatment outcome, mortality and their predictors among HIV-associated tuberculosis patients , 2012, International journal of STD & AIDS.

[28]  F. Behets,et al.  Mortality among tuberculosis patients in the Democratic Republic of Congo. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[29]  R. Chaisson,et al.  Antiretroviral Therapy for Prevention of Tuberculosis in Adults with HIV: A Systematic Review and Meta-Analysis , 2012, PLoS medicine.

[30]  S. McCormack,et al.  The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UK , 2012, International journal of STD & AIDS.

[31]  R. Walensky,et al.  Loss to Follow-Up and Mortality Among HIV-Infected People Co-Infected With TB at ART Initiation in Durban, South Africa , 2012, Journal of acquired immune deficiency syndromes.

[32]  Y. Manabe,et al.  Strengthening Public Laboratory Service in Sub-Saharan Africa: Uganda Case Study , 2011 .

[33]  M. Dimairo,et al.  Risk factors for mortality in smear-negative tuberculosis suspects: a cohort study in Harare, Zimbabwe. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[34]  Eduardo Gotuzzo,et al.  Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study , 2011, The Lancet.

[35]  S. Squire,et al.  A systematic review of risk factors for death in adults during and after tuberculosis treatment. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[36]  J. Nkengasong,et al.  Laboratory Diagnosis of Tuberculosis in Resource-Poor Countries: Challenges and Opportunities , 2011, Clinical Microbiology Reviews.

[37]  Philippe Glaziou,et al.  Tuberculosis mortality in HIV-infected individuals: a cross-national systematic assessment , 2011, Clinical epidemiology.

[38]  W. Fawzi,et al.  Factors associated with mortality in HIV-infected and uninfected patients with pulmonary tuberculosis , 2009, BMC public health.

[39]  S. Akksilp,et al.  HIV-associated extrapulmonary tuberculosis in Thailand: epidemiology and risk factors for death. , 2009, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[40]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[41]  L. Thomson,et al.  A health systems assessment of the KwaZulu-Natal tuberculosis programme in the context of increasing drug resistance. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[42]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2008, Journal of clinical epidemiology.

[43]  G. Bjune,et al.  A systematic review of delay in the diagnosis and treatment of tuberculosis , 2008, BMC public health.

[44]  J. Musser,et al.  Mortality associated with central nervous system tuberculosis. , 2007, The Journal of infection.

[45]  Matthias Egger,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies , 2007, PLoS medicine.

[46]  Paul Nunn,et al.  Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes , 2007, The Lancet.

[47]  Stef van Buuren,et al.  Multiple imputation of discrete and continuous data by fully conditional specification , 2007 .

[48]  E. Kourbatova,et al.  Risk factors for mortality among patients with extrapulmonary tuberculosis at an academic inner-city hospital in the US , 2006, European Journal of Epidemiology.

[49]  A. Harries,et al.  Mortality in smear-negative tuberculosis patients in Phalombe. , 2004, Malawi medical journal : the journal of Medical Association of Malawi.

[50]  E Declercq,et al.  Optimal tuberculosis case detection by direct sputum smear microscopy: how much better is more? , 2002, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[51]  C. Whitty,et al.  'Smear-negative' pulmonary tuberculosis in a DOTS programme: poor outcomes in an area of high HIV seroprevalence. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[52]  A. Harries,et al.  What causes smear-negative pulmonary tuberculosis in Malawi, an area of high HIV seroprevalence? , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[53]  A. Harries,et al.  Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa , 2001, AIDS.

[54]  S. Lawn,et al.  Pulmonary tuberculosis in adults: factors associated with mortality at a Ghanaian teaching hospital. , 1999, West African journal of medicine.

[55]  A. Banerjee,et al.  Treatment outcome of patients with smear-negative and smear-positive pulmonary tuberculosis in the National Tuberculosis Control Programme, Malawi. , 1999, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[56]  S. Hulley,et al.  Predictors of Mortality among HIV-infected Women in Kigali, Rwanda , 1992, Annals of Internal Medicine.

[57]  D. Rubin Multiple imputation for nonresponse in surveys , 1989 .

[58]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[59]  Vital Hepatitis Std Aids,et al.  Reported tuberculosis in the United States 2013 , 2014 .

[60]  A. Harries,et al.  Tuberculosis and HIV: current status in Africa. , 1997, AIDS.